| Previous Close | N/A |
| YTD Return | N/A |
| Expense Ratio (net) | N/A |
| Category | N/A |
| Last Cap Gain | N/A |
| Morningstar Rating | N/A |
| Morningstar Risk Rating | N/A |
| Sustainability Rating | N/A |
| Net Assets | N/A |
| Beta (3Y Monthly) | N/A |
| Yield | N/A |
| 5y Average Return | N/A |
| Holdings Turnover | N/A |
| Last Dividend | N/A |
| Average for Category | N/A |
| Inception Date | N/A |
LAVAL, Quebec , July 8, 2019 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") will release its second-quarter 2019 financial results on Tuesday, Aug. 6, 2019 . Bausch ...
Moody's Investors Service ("Moody's") assigned a Ba2 rating to the new senior secured note offering of Bausch Health Companies Inc. ("Bausch Health"), and a B3 rating to the new senior unsecured note offering of Bausch Health Americas, Inc. (formerly known as Valeant Pharmaceuticals International), guaranteed by Bausch Health. There are no changes to Bausch Health's other ratings including the B2 Corporate Family Rating, the B2-PD Probability of Default Rating, the Ba2 senior secured rating, B3 senior unsecured rating and SGL-1 Speculative Grade Liquidity Rating. The transaction is credit positive because it will extend Bausch Health's debt maturities.
Heading into December, biotech stocks held up fairly well in 2018. Evaluate Pharma , a firm specializing in data-driven news and analysis in biotech, compiled a list of blockbuster drugs in the works with ...
BRIDGEWATER, N.J., Dec. 5, 2018 /PRNewswire/ -- Bausch + Lomb, a leading global eye health company and wholly owned subsidiary of Bausch Health Companies Inc. (NYSE/TSX: BHC), today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for Bausch + Lomb ULTRA® Multifocal for Astigmatism contact lenses, the first multifocal toric lens to be available as a standard offering in the eye care professional's fit set. "Eye care professionals have routinely stressed the need to have a readily available contact lens that addresses both presbyopia and astigmatism, underscoring the critical vision needs of this growing patient population," said Joe Gordon, U.S. president, Bausch + Lomb.
Moody's Investors Service ("Moody's") upgraded the ratings of Bausch Health Companies Inc. ("Bausch Health") including the Corporate Family Rating to B2 from B3, the Probability of Default Rating to B2-PD from B3-PD, the senior secured rating to Ba2 from Ba3 and the senior unsecured rating to B3 from Caa1. "The upgrade reflects continued progress in Bausch Health's turnaround including organic growth in major business lines, resolution of the Xifaxan patent challenge, and Moody's expectation for continued debt reduction," stated Michael Levesque, Moody's Senior Vice President.
LAVAL, Quebec, Oct. 30, 2018 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) and its dermatology business, Ortho Dermatologics, one of the largest prescription dermatology health care businesses, today announced the U.S. launch of ALTRENOTM (tretinoin) Lotion, 0.05% for the topical treatment of acne vulgaris in patients 9 years of age and older. ALTRENO Lotion is the first and only tretinoin available in a lotion for acne.
LAVAL, Quebec, Oct. 11, 2018 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) and its dermatology business, Ortho Dermatologics, one of the largest prescription dermatology health care businesses, today announced that the Journal of Drugs in Dermatology has published results of two identical Phase 3, multicenter, randomized, double-blind, vehicle-controlled, parallel group studies examining the efficacy and safety of ALTRENOTM (tretinoin) Lotion, 0.05%, the first formulation of tretinoin, a retinoid, in a lotion indicated for the topical treatment of acne vulgaris in patients 9 years of age and older.1 The U.S. Food and Drug Administration approved the New Drug Application for ALTRENO Lotion on Aug. 24, 2018. In the studies, ALTRENO Lotion was shown to have significantly greater efficacy compared to vehicle in achieving treatment success, which was defined as at least a two-grade improvement from baseline in a global severity by Evaluator Global Severity Score (EGSS) and 'clear' or 'almost clear' skin.
Bill Ackman has seen better days. In October 2018, CNBC reported that Ackman's Pershing Square Capital made a$900 million bet on Starbucks. It was reported in February 2018, Ackman exited his entire $1-billion short bet against Herbalife. The fund faced a wave of redemption from institutional investors like the Blackstone Group and many asset managers like JP Morgan are no longer recommending it to clients, reported the Wall Street Journal in April.